Monte Rosa Therapeutics, Inc

PepGen, Inc., based in Boston, MA, is dedicated to developing a new generation of disease-modifying therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. The company aims to create therapeutics that safely and effectively target the root causes of serious genetic neuromuscular and neurological diseases. With a focus on advancing transformative therapies, PepGen is committed to pioneering science in the field of genetic therapies. Their clinical development pipeline includes promising programs, underscoring their dedication to addressing unmet medical needs. Generated from the website

Pyxis Oncology, Inc., located in Boston, is dedicated to developing therapeutics for difficult-to-treat cancers. The company is focused on charting a course towards innovative solutions to address the challenges of these complex diseases. Generated from their website's infomation

Paratek Pharmaceuticals, based in Boston, MA, is a biopharmaceutical company dedicated to addressing the critical global public health issue of antimicrobial resistance (AMR). With a focus on developing innovative treatment options for complex medical issues, Paratek is committed to combatting AMR through responsible antibiotic use, improved surveillance, and research into new antibiotics. Grounded in a mission to save lives, Paratek's FDA-approved tetracycline-class antibiotic, NUZYRA, targets adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. The company's disciplined team of experts is driven to provide new technologies that can defeat superbugs and contribute to a vibrant marketplace that recognizes the life-saving value of novel antibiotics.Generated from the website